The estimated Net Worth of Derek T Chalmers is at least $10.7 Million dollars as of 7 September 2021. Derek Chalmers owns over 20,000 units of Cara Therapeutics Inc stock worth over $287,507 and over the last 21 years he sold CARA stock worth over $6,994,525. In addition, he makes $3,433,620 as President, Chief Executive Officer, and Director at Cara Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Derek Chalmers CARA stock SEC Form 4 insiders trading
Derek has made over 38 trades of the Cara Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of CARA stock worth $309,400 on 7 September 2021.
The largest trade he's ever made was selling 25,000 units of Cara Therapeutics Inc stock on 14 July 2017 worth over $376,250. On average, Derek trades about 8,278 units every 40 days since 2004. As of 7 September 2021 he still owns at least 991,405 units of Cara Therapeutics Inc stock.
You can see the complete history of Derek Chalmers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Derek Chalmers biography
Dr. Derek T. Chalmers Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Chalmers has over 25 years’ experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding Cara, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow. Dr. Chalmers’ qualifications to sit on our Board of Directors include his leadership, executive, managerial and business experience, historical knowledge of our company and his background and experience in the biotechnology industry, including having been a founder of a prior biotechnology company.
What is the salary of Derek Chalmers?
As the President, Chief Executive Officer, and Director of Cara Therapeutics Inc, the total compensation of Derek Chalmers at Cara Therapeutics Inc is $3,433,620. There are 1 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of $3,736,190.
How old is Derek Chalmers?
Derek Chalmers is 56, he's been the President, Chief Executive Officer, and Director of Cara Therapeutics Inc since . There are 7 older and 10 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
What's Derek Chalmers's mailing address?
Derek's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR, STAMFORD, CT, 06902.
Insiders trading at Cara Therapeutics Inc
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, and Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
What does Cara Therapeutics Inc do?
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
What does Cara Therapeutics Inc's logo look like?
Complete history of Derek Chalmers stock trades at Arena Pharmaceuticals Inc and Cara Therapeutics Inc
Cara Therapeutics Inc executives and stock owners
Cara Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Joana Goncalves,
Chief Medical Officer -
Derek Chalmers,
President, Chief Executive Officer, Director -
Frederique Menzaghi,
Senior Vice President, Research and Development, Chief Scientific Officer -
Scott Terrillion,
Chief Compliance Officer, General Counsel, Secretary -
Dr. Derek T. Chalmers D.Sc., Ph.D.,
Co-Founder & Sr. Advisor -
Dr. Frédérique Menzaghi,
Chief Scientific Officer and Sr. VP of R&D -
Dr. Joana Goncalves,
Chief Medical Officer -
Scott M. Terrillion,
Chief Compliance Officer, Gen. Counsel & Corp. Sec. -
Richard Makara,
VP, Head of Accounting, Controller & Principal Accounting Officer -
Martin Vogelbaum,
Lead Independent Director -
Harrison Bains,
Independent Director -
Christopher Posner,
Independent Director -
Jeffrey Ives,
Independent Director -
Thomas Charles Reilly,
Chief Financial Officer -
Christopher A. Posner,
Pres, CEO & Director -
Susan Shiff,
Director -
Richard Makara,
Vice President, Head of Accounting & Controller -
Thomas Reilly,
Chief Financial Officer -
Eric Vandal,
Sr. VP of Commercial -
Dr. Michael E. Lewis Ph.D.,
Co-Founder & Chief Scientific Advisor -
Ventures Vi Lprmv Vi, L.L.C...,
-
Josef Schoell,
Chief Financial Officer -
Dean Slagel,
Director -
Ventures Vi Lprmv Vi, L.L.C...,
-
Michael E Lewis,
Chief Scientific Advisor -
Joseph William Stauffer,
Chief Medical Officer -
Robert Medve,
Chief Medical Officer -
Ventures Vi Lp Rho Capital ...,
-
Charles Ph.D. Moller,
Director -
Biopharma Partners Iii Lpal...,
-
Edward Hurwitz,
Director -
Ryan D Maynard,
CHIEF FINANCIAL OFFICER -
Moltke Lisa Von,
-
Helen M Boudreau,